clinical trial · NCT06624059
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche·phase2·active not recruiting·n = 11
Non-Small Cell Lung CancerAlectinibCisplatinCarboplatinPemetrexed
brief summary
The objective of this study is to explore the safety of alectinib in combination with chemotherapy in participants with resectable NSCLC. Cohort B1 is a phase II cohort that will assess the safety of alectinib in combination with up to four cycles of platinum-based chemotherapy in the adjuvant setting post complete surgical resection.
started
Nov 18, 2024
primary completion
Aug 28, 2026
completion
Aug 28, 2026
last updated
Apr 8, 2026
official title
A Phase I-II, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients With Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol